Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective blood sampling in driver-mutation lung cancer patients receiving tyrosine kinase inhibitors
NL-OMON55730Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Erasmus MC. Primary endpoints: Resistance mutation plasma levels and Tyrosine kinase inhibitor pharmacokinetics. Started Mar 2017; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55730.